News Article | December 15, 2016
Why does a mole rat live 30 years but a mouse only three? With $1.5 billion in the bank, Google’s anti-aging spinout Calico is rich enough to find out. At a laboratory outside San Francisco, money from the founders of Google maintains a large number of naked mole rats. The hairless rodents require exacting, expensive conditions to thrive: they live in coöperative colonies like ants, led by a queen rat. But what is truly extraordinary is that they can live about 30 years—10 times longer than a mouse. The rodents belong to Calico Labs, short for the California Life Company. In 2013, the cofounder of Google, Larry Page, announced that his company would form Calico and fund it lavishly to carry out a long-term project, trying to sort out the causes of aging and do something about them. The company’s mission: to build a Bell Labs of aging research. It hoped to extend the human life span by coming up with a breakthrough as important, and as useful to humanity, as the transistor has been. There are reasons to think aging can be slowed in fundamental ways. Among Calico’s first hires was Cynthia Kenyon, now its vice president of aging research, who 20 years ago showed that altering a single DNA letter in a laboratory roundworm made it live six weeks instead of three. There is something hair-raising about Kenyon’s videos of old, should-be-dead worms wriggling vigorously across a petri dish. So Google’s founders created an academic-biotech hybrid they call an R&D company to follow up on such clues, providing nearly unlimited funding to a group of top researchers. Calico has hired stars like artificial-intelligence specialist Daphne Koller. With equal contributions from Google’s parent company, Alphabet, and the drug company AbbVie, it has $1.5 billion in the bank. But despite the hype around its launch—Time magazine asked, “Can Google Solve Death?”—Calico has remained a riddle, a super-secretive company that three years in hasn’t published anything of note, rebuffs journalists, and asks visiting scientists to sign nondisclosure agreements. In fact, Calico has other researchers “a little miffed,” says Felipe Sierra, director of the division of aging biology at the National Institute on Aging. “We want to know what they are doing so we can focus on other things, or collaborate. They are a research company, so what are they researching?” MIT Technology Review has learned that Calico is, in effect, an elite university research group housed within a corporate bunker, doing mostly basic science. It has more than 100 employees and has assembled a Noah’s ark of yeast, worms, and more exotic creatures like the naked mole rats, which are kept at the Buck Institute for Research on Aging, about 30 miles from Calico’s South San Francisco headquarters. What’s different about a mole rat? That is the sort of costly, open-ended question Calico can afford to ask. And then there’s the seven-year study Calico is financing that will follow 1,000 mice from birth to death to search for biomarkers of aging. Right now, there’s no proven test for a person’s “biological” age; finding one would be scientifically useful and possibly lucrative. “They don’t open the kimono much,” says Brian Kennedy, a Buck Institute scientist who interacts with Calico. “I think they believe we need a broader grasp on the biology of aging. They recognize it can’t possibly be simple.” The Google founders aren’t the first billionaires to decide that aging is the “most fundamental unsolved problem in biology,” as Calico’s press releases put it. Larry Ellison, the cofounder of Oracle, gave away $335 million to scientists studying aging before redirecting his foundation’s grants toward eliminating polio in 2013. The investor Peter Thiel has also donated to the anti-aging cause, and there’s even a $500,000 Palo Alto Longevity Prize to anyone who can radically extend the life of a mammal. The difficulty is that scientists don’t know enough about why animals age. Calico’s Hal Barron, hired from Roche to lead its drug development efforts, told the National Academy of Medicine in 2015 that there would be no short-term payoff. “We believe you have to take a very long view,” he said, “and not rush into the clinic until you really know what you are doing.” A hundred and seventy five years ago most people died from infections, not from old age. Thanks to vaccines, better nutrition, and all-around improvements in public health and medicine, life expectancy at birth in wealthy nations has doubled from 40 to around 80 years, an average gain of 2.5 years per decade. But now that we live longer, we have traded up to a new set of killers that are harder to beat: cancer, heart disease, stroke, and dementia. For all these diseases, aging is the single biggest risk factor. An 80-year-old is 40 times as likely to die from cancer as someone middle-aged. The risk for Alzheimer’s rises by 600 times. But what if it were possible to postpone all these deaths by treating aging itself? “I think we have failed in our effort to attack chronic disease when we attack them one by one,” Sierra says. “And the reason is that they have one major risk factor, which is the biology of aging.” Overarching theory David Botstein is Calico’s chief scientific officer. He is 74, with a grizzled shadow of beard reaching up from his collar. In November, I found him at a lecture hall at MIT, where he offered a rare window onto experiments under way at Calico. Botstein, a well-known Princeton geneticist whom Calico recruited out of near retirement, was in town to celebrate the birthday of a successful former student, now a sexagenarian. “The pleasure is coming to see old friends,” he says. “The not-so-pleasure is if these guys are 60, what am I?” In his lecture, Botstein described several technologies—four, in fact—that Calico has for isolating old yeast cells from the daughter cells that bud off them. (One project has the institutional-sounding name Mother Enrichment Program.) These old cells are tracked and subjected to a comprehensive analysis of which genes are turned up or turned down, a technique that is Botstein’s specialty. Botstein told me Calico is exactly what Google intended: a Bell Labs working on fundamental questions, with the best people, the best technology, and the most money. “Instead of ideas chasing the money, they have given us a very handsome sum of money and want us to do something about the fact that we know so little about aging,” says Botstein. “It’s a hard problem; it’s an unmet need; it is exactly what Larry Page thinks it is. It’s something to which no one is really in a position to pay enough attention, until maybe us.” Botstein says no one is going to live forever—that would be perpetuum mobile, or perpetual motion, which defies the laws of thermodynamics. But he says Kenyon’s experiments on worms are a “perfectly good” example of the life span’s malleability. So is the fact that rats fed near-starvation diets can live as much as 45 percent longer. The studies Botstein described in yeast cells concerned a fundamental trade-off that cells make. In good times, with lots of food, they grow fast. Under stresses like heat, starvation, or aging, they hunker down to survive, grow slowly, and often live longer than normal. “Shields down or shields up,” as Botstein puts it. Such trade-offs are handled through biochemical pathways that respond to nutrients; one is called TOR, and another involves insulin. These pathways have already been well explored by other scientists, but Calico is revisiting them using the newest technology. “A lot of our effort is in trying to verify or falsify some of the theories,” Botstein says, adding that he thinks much of the science on aging so far is best consumed “with a dose of sodium chloride.” Some molecules touted as youth elixirs that can act through such pathways—like resveratrol, a compound in red wine—never lived up to their early hype. According to Botstein, aging research is still seeking a truly big insight. Imagine, he says, doctors fighting infections without knowing what a virus is. Or think back to cancer research in the 1960s. There were plenty of theories then. But it was the discovery of oncogenes—specific genes able to turn cells cancerous—that provided scientists with their first real understanding of what causes tumors. “What we are looking for, I think above everything else, is to be able to contribute to a transformation like that,” he says. “We’d like to find ways for people to have a longer and healthier life. But by how much, and how—well, I don’t know.” Botstein says a “best case” scenario is that Calico will have something profound to offer the world in 10 years. That time line explains why the company declines media interviews. “There will be nothing to say for a very long time, except for some incremental scientific things. That is the problem.” To get there, Calico is ratcheting up its expertise and skills. Botstein says it has demonstrated it could decode a human genome from scratch, without peeking at the official genome map. That’s a difficult task requiring significant investment in computing and know-how. But Calico got the right answer, so it’s confident of accurately mapping the genome of the naked mole rat—a job he says is half done. And a precise understanding of how the mole rat’s genes are organized may hold clues to its long life. “A lot of what we do is technology development,” says Botstein. “It’s not interesting, and it’s not supposed to be interesting. It’s how you put one foot in front of the other so you don’t trip on yourself.” Big disappointment To some, Calico’s heavy bet on basic biology is a wrong turn. The company is “my biggest disappointment right now,” says Aubrey de Grey, an influential proponent of attempts to intervene in the aging process and chief science officer of the SENS Research Foundation, a charity an hour’s drive from Calico that promotes rejuvenation technology. It is being driven, he complains, “by the assumption that we still do not understand aging well enough to have a chance to develop therapies.” Indeed, some competitors are far more aggressive in pursuing interventions than Calico is. “They are very committed to these fundamental mechanisms, and bless them for doing that. But we are committed to putting drugs into the clinic and we might do it first,” says Nathaniel David, president and cofounder of Unity Biotechnology. This year, Jeff Bezos joined investors who put $127 million behind Unity, a startup in San Francisco that’s developing drugs to zap older, “senescent” cells that have stopped dividing. These cells are suspected of releasing cocktails of unhelpful old-age signals, and by killing them, Unity’s drugs could act to rejuvenate tissues. The company plans to start with a modestly ambitious test in arthritic knees. De Grey’s SENS Foundation, for its part, has funded Oisin Biotechnologies, a startup aiming to rid bodies of senescent cells using gene therapy. Other scientists say it is time to begin large human studies of “geroprotectors”—drugs that could decelerate aging altogether. One such effort is being spearheaded by gerontologists at Albert Einstein College of Medicine, in New York. The medication they hope to test, metformin, is used to treat diabetes. It cropped up as an anti-aging prospect after scientists reviewing medical records found that people taking it not only were much less likely to die than other diabetics but died at a 15 percent lower rate than all other patients. Metformin lowers blood sugar levels, one clue it may have something in common with a low-calorie diet. But getting a study off the ground hasn’t been easy. To convince the U.S. Food and Drug Administration to approve the trial, doctors decided to measure metformin’s effectiveness in preventing three separate diseases: heart attack, dementia, and cancer. “They do not recognize aging as a disease, so what we have done is choose diseases of aging with minimal overlap in their causes,” says Steven Austad, a biologist at the University of Alabama at Birmingham and scientific director of the American Federation for Aging Research, which has endorsed the metformin study. “If it simultaneously delays them, that would indicate a slowed rate of aging.” The trial is designed to involve 6,000 people and would last six years. It would be the first large study of a geroprotector in volunteers, according to S. Jay Olshansky, a public health researcher at the University of Illinois at Chicago. He therefore rates the trial as significant no matter whether it flops or, as he hopes, sets off “the most groundbreaking events in public health in this century.” The only problem is who will pay for the trial, expected to cost $65 million. The chance the NIH will pay for the entire study is “remote,” says Austad, and since metformin is an old drug not covered by patents, drug companies aren’t interested either. Instead, Olshansky and Austad are going with what’s become a favorite play in research on aging: they plan to hit up billionaires for the money. Funding a groundbreaking advance, Olshansky promises potential investors, could be their “ticket to immortality.” Playing the long game The science of aging is easy to disregard, given its long historical connection to alchemy, quacks, and vitamin pushers. Even now, many scientists do their utmost to avoid the phrase “anti-aging research”—sounding as it does like a promise made on a tin of skin cream. “There are a lot of charlatans in aging research. I should be careful in what I say, but it attracts pretty quirky people,” says Gary Churchill, a mouse geneticist at the Jackson Laboratory, in Bar Harbor, Maine. It can’t help, either, that the people who bankroll this science keep saying they hope to live forever. Bill Maris, the former head of Google Ventures who hatched the idea for Calico, has said he thinks it is possible people could live “for 500 years.” That’s pretty unlikely. In that sense, Calico’s creation of a strictly controlled research fortress staffed by recognized leaders makes sense as an inoculum against hokum, maybe even from the people paying the bills. “They are playing the long game,” Churchill says. “It’s a good strategy. It could leave them positioned a decade from now to have something.” Churchill’s work with Calico gives some idea of how long it could take. In April 2016, the company agreed to pay for a large experiment at Jackson Labs to search for a “biomarker” of aging—a molecule, which they hope to find in the blood, whose quantity or properties change with “biological” age, not just with the hands on the clock. Such a diagnostic could be extraordinarily useful, and profitable. But searching for such a marker is not cheap. At Jackson Labs, Churchill’s team plans to follow 1,000 mice, drawing blood and placing them inside special cages where food and water intake can be precisely measured and the rodents’ droppings and urine collected. Half the mice will be on a calorie-restricted diet to extend their lives—necessary to confirm whether a biomarker really tags them as biologically younger. The experiment will generate millions of readings—for levels of growth hormones and glucose, among other things. Churchill wouldn’t say how much Calico is paying, but simply feeding that many mice could cost $3 million. “We’ve mapped it out, planned it. It’s immense, and we’d never be able to do this with the NIH,” he says. “The willingness to invest in the long term is the most appealing thing about Calico.” Churchill says the ideal biomarker of aging would actually estimate how much longer you have left to live, barring any unforeseen events. And the readout would change if you took a drug or adopted a diet that somehow rescheduled your appointment with the Grim Reaper. With a test like that, companies could see whether their drugs actually influenced aging without waiting many, many years for the answer. Finding such a blood marker would be the kind of breakthrough that aging research so desperately needs—and that Calico was created to discover.
Fuellen G.,University of Rostock |
Adjaye J.,Max Planck Institute for Molecular Genetics |
De Grey A.,SENS Foundation |
Lepperdinger G.,Austrian Academy of Sciences |
And 3 more authors.
Rejuvenation Research | Year: 2010
Evidence is accumulating that the first genuine antiaging interventions (e.g., approved pharmaceutical, nutriceutical, and stem-cell-based therapies) will become available within the next decades. Model organism data, next-generation sequencing, and further advances call for sophisticated large-scale data analysis. To present the state-of-the art and to talk about upcoming tasks and challenges in the bioinformatics and systems biology of aging-related data, a workshop on Bioinformatics in Ageing Research convened leading experts from Europe on May 4-5, 2010, in Rostock/Warnemünde. This meeting report summarizes talks and gives some outlook into future developments. © 2010 Mary Ann Liebert, Inc.
News Article | April 25, 2016
Zoltan Istvan is widely known as the leader of the Transhumanist movement through his well-publicized presidential campaign. However, there have been multiple past leaders, including Dr. James Hughes, the former head of the World Transhumanist Association (the organization now known as Humanity+). The basic political difference between the two futurist thought leaders is that one is a libertarian (Istvan) and one is a democratic socialist (Hughes). But Istvan and Hughes are are also emblematic of the East-West American intellectual divide; Istvan is a shiny new product of Silicon Valley’s rabid individualism and venture capitalist approach to business and politics, while Hughes has been a student of history and sociology in the hallowed halls of New England academia and an activist of the far-left for decades. Naturally, some prickliness has emerged between the old guard and Istvan, specifically related to the way he has taken the movement and transformed the idea of Transhumanism into a reflection of his own ideology through his Transhumanist Party. “Today within the attempt to grapple with transhumanist politics, we see a wide variety of political views,” said Hughes during his lecture on Thursday night. “And there is quite a vigorous debate about market versus state, and egalitarianism versus libertarianism.” For the first time, Hughes and Istvan met on the debate stage, in a small classroom auditorium at the Harvard Kennedy School in Cambridge, Mass. It wasn’t exactly a clash of ideas so much as a clang. It’s clear that Transhumanists on either side of the political spectrum share a basic tenet of the philosophy, the vague notion of the need to use science and technology to make humanity better, but from there on out, everything else is up for debate. Here are takeaways on a few of the big politics sticking points Transhumanists disagree on. Istvan has advocated for a flat tax, but also supports universal basic income, as well as free education: “A universal basic income would give everyone enough money to survive, have food, have a roof over their head. But I only support it if it’s going to make government at least equal or smaller. There is a Libertarian attitude for that, probably in ten years, when we start giving our jobs to AI.” Hughes wants to increase taxes on the wealthy: “To believe that we are going to eliminate taxation and have a universal basic income, there is a problem. In order to have a real universal basic income, which I agree is going to be necessary in the future, we need to also a have a redistributive state. We are going to radically increase the progressivity of taxation in the United States in order to make sure everyone gets fed. “ Istvan is a militant atheist who rejects his Catholic upbringing: “We live in a culture that for thousands of years has embraced a Judeo-Christian framework that really teaches us that the best way to live to live a good life and then to die and meet a maker in heaven. And it doesn’t matter if it’s the president swearing on the Bible, or the Pledge of Allegiance having the word ‘God’ in it, it’s all around us. And even if we don’t believe in it, it’s still our framework and it leads to this culture of ‘deathism’.” Hughes is a Buddhist scholar: “Buddhism and Hinduism are much more fluid in the understanding between humanity and gods [as opposed to the Abrahamic faiths], where their gods are flying around on moon discs, with eight arms and green skin and 12 heads, and some of them are half-animal. It’s also a much more science fiction future that they imagine, and it’s also a much longer one.” Istvan, whose wife is a doctor: “In my Transhumanist Bill of Rights, I advocate morphological freedom, the freedom to do what you want with your own body, as long as it’s not hurting somebody else… When biohackers want to experiment on themselves, I think they need to be able to do it, and I wish we had a system where surgeons can perform [body hacks] without worrying about their careers at stake. “An article that came out recently was about two friends who want to get brain implants so they can interface with artificial intelligence… They have to find a doctor on the black market, and that’s a problem. We need to create a scenario where people can do whatever they want. “With some of the CRISPR gene technology coming out, and people trying to grow tails and whatever they’re trying to do, there’s going to be new ways of looking at ourselves as a species and I very much think we need to embrace that.” Hughes, who is a bioethicist: “I think that we have a Food and Drug Administration for a reason. The history of medicine illustrates amply that the ‘buyer beware’ stance doesn’t work very well for people. We end up with all kinds of bad drugs, and we should agree that there must be some kind of regulatory mechanism to ensure that things are safe. “I don’t believe in medical tourism… I think we need transnational regulation of medicine and we need international harmonization [the idea that medical ethics standards and trade practices are accepted and agreed upon, across international boundaries]. It’s one of the things that I think would solve some of the regulatory bottlenecks of the FDA. International harmonization comes with risks, I understand that. But I don’t think the answer is the Wild West.” Hughes, in opposition to Istvan’s Transhumanist Party: “I argue that strategically, the way Transhumanists should engage around politics is with caucuses within parties. Caption: Zoltan Istvan pictured on his coffin-shaped Immortality Bus outside Richmond, VA in December 2015. Photo by Alex Pearlman “Part of the job of techno-progressives is to take a futurist perspective to [other movements] and build within those movements and not in opposition to them. And as an example, I have attempted to be pretty nuanced on the disability issue—Zoltan is tone deaf… We have to sensitively engage around these issues.” Istvan, in response to the accusation of ‘tone deafness’: “I think that when James talks about me being tone deaf, I am 100 percent guilty. But to me, the Transhumanism movement is too small to worry about every single little detail. We are still a developing movement. We’ll work it out later. “I had to make a decision quite early on to be tone deaf, and to put forth policies that were just sensational enough to get picked up by the media and just believable enough to make sense. [Building a party] takes years. The Libertarian party is finally going to be on the ballot in all 50 states this year, and that has taken since 1979. So we’re like a baby… But the next go-around, if the Transhumanist party is still here, there probably will be a national caucus. “Ultimately, I think the two-party system in America is a bummer. It sucks”. Hughes believes we need to deal with climate change, but we must engage experts: “We could probably sell environmentalism better if we had a sexy, high-tech, non-pastoral vision for what a sustainable future would be. “The key sustainability factor is having technology… but let’s first deal with the issues facing the environment before we begin changing ourselves.” Istvan thinks humans can change themselves to adapt to a changing planet: “I have advocated, instead of trying to reduce the carbon footprint, instead we should be inventing brand new technologies. We worry so much about the ozone layer, but I’ve advocated for things like a bionic lung to deal with the atmosphere. More importantly, we can use new technologies like CRISPR to grow back the rainforest, or eat meatless meat... We could replenish the planet in ten or fifteen years.” Istvan insists aging research needs a massive influx of funding: “The fundamentalism that is dedicated toward this idea that many people don’t mind dying is what needs to be changed. It’s why I drove a coffin across the county. We can change this. It’s not a matter of religion or right or wrong. We have the science to stop it, but no one is putting any money into it. All it really needs is money. We need to wake up America and say ‘Listen, we can do this!’... I know it sounds totally radical, but a trillion dollars isn’t a lot... If we spend 15 percent of what we put into the war in Iraq, we could do that.” Caption: Zoltan Istvan pictured on his Immortality Bus outside Richmond, VA in December 2015. Photo by Alex Pearlman Hughes believes life extension research needs more social justice: “Capitalism in the United States, as we practice it, is causing middle-class Americans to have higher rates of drug abuse, alcoholism and suicide. Plus, obesity which is also class-related... “Virtually all life expectancy improvements have been social—clean sanitation systems, improved education, smaller family sizes—medicine has had almost nothing to do with improving life expectancy. If we really want to save lives, we can’t just talk about hypothetical technologies, we also have connect it to the social justice mission that will make it real for people.” ON MONEY IN THE MOVEMENT: Hughes accuses the libertarian wing of Transhumanism of being under the thumb of Silicon Valley billionaires: “Peter Thiel, who runs a billion dollar hedge fund, is also one of the principal backers of Rand Paul, Ted Cruz, and a bunch of other far-right operations in the country. And he also happens to be the financial backer of two of the most prominent Transhumanist organizations in San Francisco, the Machine Intelligence Research Institute (MIRI) and the SENS Foundation, Aubrey de Grey’s operation. “Does that mean that they are towing his political line? No. But does it establish a certain kind of constraint? The plurality of transhumanists are on the left, but the ones on the right have this disproportionate hegemonic influence in transhumanist politics.” Istvan rebuts this accusation, but supports using technology to become wealthy: “Frankly, no billionaire has come to the defense of Transhumanism so far and stuck a whole bunch of money into the social part of our movement… The Transhumanist Party has had virtually no funding. I don’t take any money for my campaign whatsoever. I have not taken a dollar, outside of the Immortality Bus. “For anyone that’s working as an engineer or a technologist or someone that’s going to be working on AI, you can all become filthy rich. I think that is important for a lot of engineers out in Silicon Valley that are working on this stuff... There will be a whole generation of billionaires made because of Transhumanism.” Hughes on Zoltan’s novel, The Transhumanist Wager: “It’s like Ayn Rand wrote Atlas Shrugged and then ran for office as a Democrat… At least in Atlas Shrugged the rich people buggered off and left everybody alone.”
Zealley B.,SENS Foundation |
De Grey A.D.N.J.,SENS Foundation
Gerontology | Year: 2013
In this viewpoint, we describe the strategies for engineered negligible senescence (SENS) concept - a simple and appealing model for the design of therapeutic interventions able to meaningfully and persistently reverse the deleterious effects of aging. We go on to outline how current or foreseeable biotechnologies could feasibly be employed to repair every currently identified category of pathogenic damage that accumulates over a human lifespan. Then, briefly, we explain why this goal is not only ethically sound, but can in fact be considered to verge on an ethical obligation. Finally, we review recent progress in some key areas of the SENS platform, including proof-of-concept research sponsored by the SENS Foundation, a charity based in California. Copyright © 2012 S. Karger AG, Basel.
De Bartolo L.,University of Calabria |
Leindlein A.,Helmholtz Center Geesthacht |
Hofmann D.,Helmholtz Center Geesthacht |
Bader A.,University of Leipzig |
And 4 more authors.
Chemical Engineering and Processing: Process Intensification | Year: 2012
The regeneration of tissues and organs has been a matter of dream and Greek mythology since ancient times as the liver regeneration in Prometheus punished by Zeus. It is now emerging a new way of treating injuries and diseases, which is based on regenerative medicine.Clinical and social needs related to the aging and diseases led to innovative medical therapies that will enable the repairing and regeneration of damaged tissues and organs.This position paper gives a future vision for 2030 of the biohybrid organs and tissues that will be used for patient therapy and in the overcoming the age-related pathologies. The research strategies for the next 20 years will focus on the implantation of bioartificial tissues and the induction of the regeneration. Biomaterials and bioreactor technologies will play pivotal roles in the regeneration and in the production of individualized biological implants. Future challenges will include the development of multifunctional biohybrid organs and tissues. These concepts are based on a multidisciplinary approach bringing together various scientific fields, which will contribute to the new and fascinating medical therapies. © 2011 Elsevier B.V.
De Grey A.D.N.J.,SENS Foundation
Gerontology | Year: 2013
In their article in this issue, Olshansky and Carnes [Gerontology 2013;59:85-92] spell out in perhaps the most explicit terms yet a view which they have long espoused: that increases in longevity will inevitably slow down in decades to come, since the rate of biomedical progress that everyone agrees would be necessary to avoid such a slowdown is far too dramatic to be plausible. By doing so, they also betray more explicitly than ever before the flaws in their own logic. It is ironic that these flaws, unlike the work they critique, are actually quite closely analogous to the flaws in Zeno's paradox. Since others are offering their own comments on other parts of the article, I shall restrict my remarks on the article to those passages which refer specifically to my own work, together with the conclusion. Copyright © 2012 S. Karger AG, Basel.
PubMed | SENS Foundation
Type: Comment | Journal: Gerontology | Year: 2012
In their article in this issue, Olshansky and Carnes [Gerontology 2013;59:85-92] spell out in perhaps the most explicit terms yet a view which they have long espoused: that increases in longevity will inevitably slow down in decades to come, since the rate of biomedical progress that everyone agrees would be necessary to avoid such a slowdown is far too dramatic to be plausible. By doing so, they also betray more explicitly than ever before the flaws in their own logic. It is ironic that these flaws, unlike the work they critique, are actually quite closely analogous to the flaws in Zenos paradox. Since others are offering their own comments on other parts of the article, I shall restrict my remarks on the article to those passages which refer specifically to my own work, together with the conclusion.
PubMed | SENS Foundation
Type: Journal Article | Journal: Gerontology | Year: 2013
In this viewpoint, we describe the strategies for engineered negligible senescence (SENS) concept--a simple and appealing model for the design of therapeutic interventions able to meaningfully and persistently reverse the deleterious effects of aging. We go on to outline how current or foreseeable biotechnologies could feasibly be employed to repair every currently identified category of pathogenic damage that accumulates over a human lifespan. Then, briefly, we explain why this goal is not only ethically sound, but can in fact be considered to verge on an ethical obligation. Finally, we review recent progress in some key areas of the SENS platform, including proof-of-concept research sponsored by the SENS Foundation, a charity based in California.